MAPK通路抑制联合甲状腺激素撤退促摄碘再分化治疗碘难治性分化型甲状腺癌的探索性方案
该回顾性研究评估了突变引导的MAPK通路抑制联合甲状腺激素撤退(THW)对碘难治性分化型甲状腺癌(RAIR DTC)再分化的可行性。6例患者中,NRAS突变者用曲美替尼,BRAFV600E突变者用BRAF抑制剂联合MEK抑制剂,治疗4周并THW 4周。部分患者恢复碘摄取并接受RAI治疗,影像学部分缓解,但出现3级不良反应。
要点
- 突变引导的MAPK通路抑制联合THW可使部分RAIR DTC恢复摄碘。
- BRAFV600E突变者均恢复摄碘,NRAS突变者部分恢复。
- 治疗期间需警惕3级痤疮样皮疹等不良反应。
核心结论
- 突变引导的MAPK通路抑制联合THW是RAIR DTC再分化的可行策略,可使其适合RAI治疗并获满意滞留。
研究设计与样本
- 回顾性综述,纳入2015至2017年6例携带MAPK通路驱动突变的转移性RAIR DTC患者(年龄45-70岁,4例女性)。
主要发现
- 1例NRAS突变和全部3例BRAFV600E突变患者恢复RAI摄取并接受RAI治疗,中位随访16.6个月(范围13.5-42.3个月)。
- 1例NRAS突变和2/3例BRAFV600E突变患者在3个月随访后达到影像学部分缓解。
- 2例NRAS突变患者出现3级痤疮样皮疹。
关键数值与推荐
- NRAS突变肿瘤使用MEK抑制剂(曲美替尼),BRAFV600E突变肿瘤使用BRAF联合MEK抑制(达拉非尼+曲美替尼或维莫非尼+考比替尼)4周。
- 甲状腺激素撤退4周以刺激TSH,通过124I PET/CT评估RAI摄取恢复,RAI治疗后至少3个月评估反应。
临床怎么用
- 对携带NRAS或BRAFV600E突变的RAIR DTC患者,可考虑突变引导的MAPK通路抑制联合THW以尝试再分化。
- 治疗期间需监测不良反应,尤其是3级痤疮样皮疹。
局限性
- 回顾性研究,样本量小(仅6例),随访时间有限。
- 缺乏对照组,再分化方案尚未标准化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Some patients with metastatic differentiated thyroid cancer (DTC) lack iodine avidity and are therefore unsuitable for radioactive iodine (RAI) therapy. Limited experience suggests that single-agent selective mitogen-activated protein kinase (MAPK) pathway inhibitors can restore expression of the sodium-iodide symporter rendering RAI refractory (RAIR) DTC patients amenable to RAI therapy. The aim of this study was to assess the feasibility of mutation-guided MAPK-pathway blockade combined with thyroid hormone withdrawal (THW) for redifferentiation. Methods: This is a retrospective review of metastatic RAIR DTC and driver mutation in MAPK pathway, treated on a redifferentiation protocol. All patients had metastatic disease that had never been RAI-avid and/or imaging and biochemical progression despite treatment with RAI within the past 12 months. Patients with tumors harboring an NRAS mutation were treated with an MEK inhibitor (trametinib), and tumors with a BRAFV600E mutation with combined BRAF and MEK inhibition (dabrafenib and trametinib; or vemurafenib and cobimetinib) for four weeks. Thyrotropin stimulation was performed by THW for four weeks. Restoration of RAI uptake was determined by 124I positron emission tomography/computed tomography imaging. The response was assessed at least three months post-RAI. Results: From 2015 to 2017, six patients (age 45-70, four females) received redifferentiation therapy. Three patients had an NRAS mutation; two with follicular thyroid carcinoma (FTC) and one with a poorly differentiated thyroid carcinoma (PDTC); and three patients had a BRAFV600E mutation and papillary thyroid carcinoma (PTC). One NRAS and all BRAFV600E mutation cases demonstrated restoration of RAI uptake and proceeded to RAI therapy with a median follow-up of 16.6 months (range 13.5-42.3 months). The patient with an NRAS mutation and two of three patients with a BRAFV600E demonstrated partial imaging response beyond a three-month follow-up. Grade 3 adverse events (acneiform rash) were observed in two patients with NRAS mutations. Conclusions: Mutation-guided MAPK pathway inhibition with MEK inhibitor or a combination of BRAF inhibitor and MEK inhibitor under concurrent THW is a feasible and a promising strategy to redifferentiate RAIR DTC, thereby rendering them suitable for RAI therapy with satisfactory retention following treatment.
引用
- Iravani A, Solomon B, Pattison DA, et al. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. Thyroid. 2019. PMID: 31637953. doi:10.1089/thy.2019.0143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。